**Abstracts**

**PS4:71**  
IGA ANTI-PHOSPHOLIPID ANTIBODIES IN SWEDISH CASES WITH SYSTEMIC LUPUS ERYTHEMATOSUS: ASSOCIATIONS WITH DISEASE PHENOTYPES, VASCULAR EVENTS AND DAMAGE ACCRUAL

1M Frodlund, 2A Vikerfors, 3G Grosso, 4T Sjöwall, 5K Elvin, 6A Kastbom, 7Ö Dahlström, 8E Svenungsson, 9C Sjöwall. 1Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden; 2Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Stockholm, Sweden; 3Unit of Clinical Immunology, Department of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden; 4Swedish Institute for Disability Research, Department of Behavioural Sciences and Learning, Linköping University, Linköping, Sweden; 5Department of Rheumatology and Clinical Immunology, Uppsala University, Uppsala, Sweden

**Objectives**  
IgG- and IgM-class anti-cardiolipin antibodies (aCL) and lupus anticoagulant (LA) are included in the 1997 update of the American College of Rheumatology (ACR-97) systemic lupus erythematosus (SLE) classification criteria. Despite limited evidence, IgA-aCL and IgA anti-b2-glycoprotein-I (anti-b2GPI) were included among the 2012 Systemic Lupus International Collaborating Clinics classification criteria. The present study was undertaken to evaluate IgG-/IgA-/IgM-aCL and anti-b2GPI occurrence in relation to disease phenotype, smoking habits, pharmacotherapy, APS-related events, and organ damage among Swedish SLE patients.

**Methods**  
526 SLE patients meeting ACR-97 were included. Blood donors and patients with rheumatoid arthritis or primary Sjögren’s syndrome served as controls. Serum anti-phospholipid antibodies (aPL) were analysed by enzyme-immunoassays.

**Results**  
76 (14%) SLE cases fulfilled the Sydney APS-criteria, and at least 1 aCL/anti-b2GPI isotype (IgG/IgA/IgM) occurred in 138 SLE patients (26%). 44 (8%) of the SLE cases had IgA-aCL, of whom 20 (4%) lacked IgG-/IgM-aCL. 74 (14%) tested positive for IgA anti-b2GPI. 34 (6%) being seronegative regarding IgG/IgM anti-b2GPI. 6 (1%) had manifestations compatible with APS and were seropositive regarding IgA-aCL and/or IgA anti-b2GPI in absence of IgG/IgM-aPL and LA. Positive LA- and IgG-aPL tests associated with most APS-related events and organ damage. Exclusive IgA anti-b2GPI occurrence associated inversely with Caucasian ethnicity and photosensitivity. Nephritis, smoking, LA-positivity and statin/corticosteroid-medication associated strongly with organ damage, whereas ongoing hydroxychloroquinemedication was protective.

**Conclusions**  
IgA-aPL is not uncommon in SLE (16%). Exclusive IgA anti-b2GPI ± IgA aCL associated with non-Caucasian ethnicity. IgA-aPL analysis may be of additional value among clinically suspected APS-patients testing negative for other iso-types of aPL and LA.

---

**PS4:72**  
ANTIPHOSPHOLIPID ANTIBODIES AND AUTOIMMUNE HEMOLITIC ANAEMIA IN SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE-CONTROL STUDY

1F Crisafulli, 2L Andreoli, 3F Franceschini, 4M Frassi, 5M Fredi, 6C Nalli, 7A Tincani. 1Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Italy; 2Rheumatology and Clinical Immunology Unit, Spedali Civili of Brescia, Italy

**Purpose**  
Hemolytic anaemia with reticulocitosis is included in ACR and SLICC classification criteria of Systemic Lupus Erythematosus (SLE). Some studies have assessed the relationship between antiphospholipid antibodies (aPL) and autoimmune hemolytic anaemia (AIHA) in SLE patients. Some of them had describe a correlation with the presence of Lupus...